Ad5/3-hTERT-E1A-hCD40L

AXP000070.1 · Oncolytic virus

Platform
adenovirus (Ad5/3 chimera, hTERT promoter, CD40L-armed)
Originator
University of Helsinki (Akseli Hemminki)

Names

NameTypeSource
Ad5/3-hTERT-E1A-hCD40Lpreferred name, codecurator, paper
Ad5/3-hTERT-CD40Lsynonympaper

Virus

Role
Oncolytic
Family
Adenoviridae
Virus
human adenovirus 5 (NCBI Taxonomy 28285)
Strain
Ad5/3 chimera
Replication
conditionally replicating
Modifications
hTERT promoter drives E1A; Ad3 fiber knob
Transgenes
CD40LG
Route
intratumoral, intraperitoneal, intrapleural, intravenous
Source
evidence

Approvals

No regulatory approval recorded.

Clinical trials (0)

No trial in the latest ClinicalTrials.gov snapshot names this program.

Recent changes

No changes recorded in its trials yet.

Clinical papers

No confirmed clinical papers yet.

Other papers

Preclinical studies, reviews and other papers that name it.

PubMedTitleJournalYearLinked by
PMID 22396493Immune response is an important aspect of the antitumor effect produced by a CD40L-encoding oncolytic adenovirus.Cancer research2012name in abstract: Ad5/3-hTERT-E1A-hCD40L

Notes

ATAP construct (2007-2012), written Ad5/3-hTERT-CD40L in some reports and reported elsewhere under the code CGTG-401; the code was not verified here.

How to cite

Ad5/3-hTERT-E1A-hCD40L (AXP000070.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000070.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.